L. Assersohn

2.3k total citations
21 papers, 1.2k citations indexed

About

L. Assersohn is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, L. Assersohn has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Cancer Research and 5 papers in Surgery. Recurrent topics in L. Assersohn's work include Breast Cancer Treatment Studies (6 papers), BRCA gene mutations in cancer (4 papers) and HER2/EGFR in Cancer Research (4 papers). L. Assersohn is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), BRCA gene mutations in cancer (4 papers) and HER2/EGFR in Cancer Research (4 papers). L. Assersohn collaborates with scholars based in United Kingdom, United States and Singapore. L. Assersohn's co-authors include Mitch Dowsett, Trevor J. Powles, Andreas Makris, R.K. Gregory, Edison T. Liu, David Cunningham, J. Oates, T.J. Powles, John Suckling and Janet E. Husband and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and The American Journal of Human Genetics.

In The Last Decade

L. Assersohn

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Assersohn United Kingdom	15	513	430	319	243	230	21	1.2k
S.M. O'Reilly United Kingdom	14	641 1.2×	354 0.8×	225 0.7×	294 1.2×	162 0.7×	26	1.2k
Anna Cardillo Italy	17	734 1.4×	613 1.4×	252 0.8×	173 0.7×	151 0.7×	29	1.1k
Ingvil Mjaaland Norway	20	885 1.7×	822 1.9×	302 0.9×	369 1.5×	239 1.0×	43	1.6k
Skye Hongiun Cheng Taiwan	23	562 1.1×	382 0.9×	269 0.8×	420 1.7×	181 0.8×	32	1.7k
Malgorzata Tuxen Denmark	18	687 1.3×	318 0.7×	394 1.2×	282 1.2×	153 0.7×	33	1.8k
R. Largillier France	14	940 1.8×	527 1.2×	162 0.5×	334 1.4×	198 0.9×	47	1.5k
Ernesto Wasserman United States	17	812 1.6×	377 0.9×	418 1.3×	358 1.5×	135 0.6×	35	1.2k
Steffen Kahlert Germany	17	658 1.3×	354 0.8×	347 1.1×	140 0.6×	379 1.6×	46	1.2k
Yidong Zhou China	23	670 1.3×	681 1.6×	367 1.2×	257 1.1×	126 0.5×	93	1.4k
Dominique Berton-Rigaud France	18	1.0k 2.0×	277 0.6×	217 0.7×	238 1.0×	226 1.0×	73	1.8k

Countries citing papers authored by L. Assersohn

Since Specialization

Citations

This map shows the geographic impact of L. Assersohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Assersohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Assersohn more than expected).

Fields of papers citing papers by L. Assersohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Assersohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Assersohn. The network helps show where L. Assersohn may publish in the future.

Co-authorship network of co-authors of L. Assersohn

This figure shows the co-authorship network connecting the top 25 collaborators of L. Assersohn. A scholar is included among the top collaborators of L. Assersohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Assersohn. L. Assersohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dodson, Andrew, L. Assersohn, Anne Rigg, et al.. (2017). Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. Breast Cancer Research and Treatment. 168(1). 249–258. 6 indexed citations

King, Judy, et al.. (2011). Hormone replacement therapy and women with premature menopause – A cancer survivorship issue. European Journal of Cancer. 47(11). 1623–1632. 26 indexed citations

Léary, Alexandra, L. Assersohn, David Cunningham, et al.. (2008). A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 64(3). 455–462. 24 indexed citations

Kote‐Jarai, Zsofia, Trevor J. Powles, Gillian Mitchell, et al.. (2006). BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Letters. 247(2). 259–265. 10 indexed citations

Padhani, Anwar R., Carmel Hayes, L. Assersohn, et al.. (2006). Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results. Radiology. 239(2). 361–374. 193 indexed citations

O’Brien, Mary, Anne Rigg, Alexandra Léary, et al.. (2006). Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. British Journal of Cancer. 95(12). 1632–1636. 96 indexed citations

Urruticoechea, Ander, Caroline Archer, L. Assersohn, et al.. (2005). Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. British Journal of Cancer. 92(3). 475–479. 14 indexed citations

Assersohn, L., Gina Brown, David Cunningham, et al.. (2003). Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Annals of Oncology. 15(1). 64–69. 110 indexed citations

Assersohn, L., A. Norman, David Cunningham, et al.. (2003). A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer. 39(8). 1121–1128. 15 indexed citations

10.

Assersohn, L. & Stephen R.D. Johnston. (2003). Postmenopausal Metastatic Breast Cancer. 2(2). 95–109. 1 indexed citations

11.

Assersohn, L., Janine Salter, T.J. Powles, et al.. (2003). Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer. Breast Cancer Research and Treatment. 82(2). 113–123. 54 indexed citations

12.

Sotiriou, Christos, Trevor J. Powles, Mitch Dowsett, et al.. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research. 4(3). R3–R3. 187 indexed citations

13.

Assersohn, L., Lisa Gangi, Yingdong Zhao, et al.. (2002). The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses.. PubMed. 8(3). 794–801. 68 indexed citations

14.

Assersohn, L., B.E. Souberbielle, Mary O’Brien, et al.. (2002). A Randomized Pilot Study of SRL172 ( ) in Patients with Small Cell Lung Cancer (SCLC) Treated with Chemotherapy. Clinical Oncology. 14(1). 23–27. 24 indexed citations

15.

Kote‐Jarai, Zsofia, S. Ashley, DF Easton, et al.. (2000). BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial. Breast Cancer Research. 2(S1). 1 indexed citations

16.

Eeles, Rosalind A., S. Ashley, Douglas F. Easton, et al.. (1999). BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial. The American Journal of Human Genetics. 65(4). 124. 2 indexed citations

17.

Dowsett, Mitch, Caroline Archer, L. Assersohn, et al.. (1999). Clinical studies of apoptosis and proliferation in breast cancer.. Endocrine Related Cancer. 6(1). 25–28. 46 indexed citations

18.

Assersohn, L., T.J. Powles, S. Ashley, et al.. (1999). Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Annals of Oncology. 10(12). 1451–1456. 43 indexed citations

19.

Chang, Jian, T.J. Powles, D. Craig Allred, et al.. (1999). Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer. Journal of Clinical Oncology. 17(10). 3058–3063. 185 indexed citations

20.

Assersohn, L., A. Norman, David Cunningham, et al.. (1999). Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. British Journal of Cancer. 79(11-12). 1800–1805. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact